Neurocognitive disorders in Parkinson's disease;Neurokognitív zavarok diagnosztizálási és kezelési leheto″ségei Parkinson-kórban

Orvosi Hetilap

Volumn 156, Issue 23, 2015, Pages 915-926

  Lucza, Tivadar ^a   Karádi, Kázmér ^a   Komoly, Sámuel ^b   Janszky, József ^b,c   Kállai, János ^a   Makkos, Attila ^b   Kovács, Márton ^b   Weintraut, Rita ^a   Deli, Gabriella ^b   Aschermann, Zsuzsanna ^b   Kovács, Norbert ^b,c  

^a UNIVERSITY OF PÉCS   (Hungary)

^b Neurologiai Klinika   (Hungary)

^c UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Dementia; Mild cognitive impairment; Neurocognitive disorder; Parkinson's disease; Screening

Indexed keywords

ADDENBROOKE COGNITIVE EXAMINATION; ASSESSMENT OF HUMANS; COGNITIVE DEFECT; DEMENTIA; DISEASE ASSOCIATION; DSM-5; HUMAN; MATTIS DEMENTIA RATING SCALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; MONTREAL COGNITIVE ASSESSMENT; PARKINSON DISEASE; REVIEW; CONCEPT FORMATION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIFFERENTIAL DIAGNOSIS; EDUCATIONAL STATUS; HUNGARY; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGY; RISK REDUCTION; SEVERITY OF ILLNESS INDEX; STANDARDS;

CHOLINESTERASE INHIBITOR;

CHOLINESTERASE INHIBITORS; CONCEPT FORMATION; DEMENTIA; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; EDUCATIONAL STATUS; HUMANS; HUNGARY; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; RISK REDUCTION BEHAVIOR; SEVERITY OF ILLNESS INDEX;

EID: 84940099535     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/650.2015.30159     Document Type: Review

References (58)

1. Leroi, I., McDonald, K., Pantula, H., et al.: Cognitive impairment in Parkinson disease: impact on quality of life, disability, and caregiver burden. J. Geriatr. Psychiatry Neurol., 2012, 25(4), 208-214.
2. Kovács, N.: Parkinson's disease from the perspective of general practice. [A Parkinson-kór a gyakorló orvosok szemszögébo″l.] Lege Artis Medicinae, 2014, 24(8-9), 406-414. [Hungarian]
3. Yarnall, A. J., Breen, D. P., Dunc an, G. W., et al.: Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study. Neurology, 2014, 82(4), 308-316.
4. Pfeiffer, H. C., Løkkegaard, A., Zoetmulder, M., et al.: Cognitive impairment in early-stage non-demented Parkinson's disease patients. Acta Neurol. Scand., 2014, 129(5), 307-318.
5. Halliday, G. M., Leverenz, J. B., Schneider, J. S., et al.: The neurobio logical basis of cognitive impairment in Parkinson's disease. Mov. Disord., 2014, 29(5), 634-650.
6. Poletti, M., Emre, M., Bonuccelli, U.: Mild cognitive impairment and cognitive res erve in Parkinson's disease. Parkinsonism Relat. Disord., 2011, 17(8), 579-586.
7. Godefroy, O., Azouvi, P., Robert, P., et al.: Dysexecutive syndrome: diagnostic criteria and validatio n study. Ann. Neurol., 2010, 68(6), 855-864.
8. Karádi, K., Lucza, T., Aschermann, Z., et al.: Visuospatial impairment in Parkinson's disease: the role of laterality. Laterality, 2015, 20(1), 112-127.
9. Sanyal, J., Banerjee, T. K., Rao, V. R.: Dementia and cognitive impairment in patients with Parkinson's disease from India: a 7-year pro spective study. Am. J. Alzheimers Dis. Other Demen., 2014, 29(7), 630-636.
10. Reid, W. G., Hely, M. A., Morris, J. G., et al.: Dementia in Parkinson's disease: a 20-year neuropsychological study (Sydney Multicentre Study). J. Neurol. Neurosurg. Psychiatry, 2011, 82(9), 1033-1037.
11. Balzer-Geldsetzer, M., Costa, A. S., Kronenbürger, M., et al.: Parkinson's disease and dementia: a longitudinal study (DEMPARK). Neuroepidemiology, 2011, 37(3-4), 168-176.
12. Marder, K.: Cognitive impairment and dementia in Parkinson's disease. Mov. Disord., 2010, 25(Suppl. 1), S110-S116.
13. Aarsland, D., Andersen, K., Larsen, J. P., et al.: Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch. Neurol., 2003, 60(3), 387-392.
14. Martínez-Horta, S., Kulisevsky, J.: Is all cognitive impairment in Parkinson's disease "mild cognitive impairment"? J. Neural. Transm., 2011, 11 8(8), 1185-1190.
15. Janvin, C. C., Larsen, J. P., Aarsland, D., et al.: Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. Mov. Disord., 2006, 21(9), 1343-1349.
16. Palavra, N. C., Naismith, S. L., Lewis, S. J.: Mild cognitive impairment in Parkinson's disease: a review of current concepts. Neurol. Res. Int., 2013, 2013, 576091.
17. Kovács, N., Balás, I., Llumiguano, C., et al.: Deep brain stimulation: a novel possibility for the tre atment of movement disorders. [Mély agyi stimuláció: új perspektíva a mozgászavarok kezelésében.] Lege Artis Medicinae, 2009, 19(2), 119-126. [Hungarian]
18. American Psychiatric Association: Diagnostic and statistical manual of mental disorders. American Psychiatric Publishing, Washington, 2000.
19. Emre, M., Aarsland, D., Brown, R., et al.: Clinica l diagnostic criteria for dementia associated with Parkinson's disease. Mov. Disord., 2007, 22(12), 1689-1707.
20. Dubois, B., Burn, D., Goetz, C., et al.: Diagnostic procedures for Parkinson's disease dementia: recommendations from the Movement Disorder Society Task Force. Mov. Disord., 2007, 22(16), 2314-2324.
21. Litvan, I., Goldman, J. G., Tröster, A. I., et al.: Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov. Disord., 2012, 27(3), 349-356.
22. Martinez-Martin, P., Falup-Pecurariu, C., Rodriguez-Blazquez, C., et al.: Dementia associated with Parkinson's disease: applying the Movement Disorder Society Task Force criteria. Parkinsonism Relat. Disord., 2011, 17(8), 621-624.
23. Geurtsen, G. J., Hoogland, J., Goldman, J. G., et al.: Parkinson's disease mild cognitive impairment: application and validation of the criteria. J. Parkinsons Dis., 2014, 4(2), 131-137.
24. Hobson, P., Meara, J.: Mild cognitive impai rment in Parkinson's disease and its progression onto dementia: a 16-year outcome evaluation of the Denbighshire cohort. Int. J. Geriatr. Psychiatry, 2015 Feb 11. [Epub ahead of print]
25. Domellöf, M. E., Ekman, U., Forsgren, L., et al .: Cognitive function in the early phase of Parkinson's disease, a five-year followup. Acta Neurol. Scand., 2015 Feb 3. [Epub ahead of print]
26. Szeto, J. Y., Mowszowski, L., Gilat, M., et a l.: Assessing the utility of the Movement Disorder Society Task Force Level 1 diagnostic criteria for mild cognitive impairment in Parkinson's disease. Parkinsonism Relat. Disord., 2015, 21(1), 31-35.
27. American Psychiatric Association: Diagnostic and statistical manual of mental disorders. American Psychiatric Publishing, Arlington, 2013.
28. Kaszás, B., Kovács, N., Balás, I., et al.: Sensitivity and specificity of Adden brooke's Cognitive Examination, Mattis Dementia Rating Scale, Frontal Assessment Battery and Mini Mental State Examination for diagnosing dementia in Parkinson's disease. Parkinsonism Relat. Disord., 2012, 18(5), 553-556.
29. Chou, K. L., Amick, M. M., Brandt, J., et al.: A recommended scale for cognitive screening in clinical trials of Parkinson's disease. Mov. Disord., 2010, 25(15), 2501-25 07.
30. Feher, E. P., Mahurin, R. K., Doody, R. S., et al.: Establishing the limits of the Mini-Mental State. Examination of 'subtests'. Arch. Neurol., 1992, 49(1), 87-92.
31. Nasreddine, Z. S., Phillips, N. A., Bédirian, V., et al.: The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J. Am. Geriatr. Soc., 2005, 53(4), 695-699.
32. Volosin, M., Janacsek, K., Németh, D.: Hungarian version of the Montreal Cognitive Assessment (MoCA) for scre ening mild cognitive impairment. [A Montreal Kognitiv Felmérés (MoCA) magyar nyelvu″ adaptálása egészséges, enyhe kognitiv zavarban és demenciában szenvedo″ ido″s személyek körében.] Psychiatr. Hung., 2013, 28(4), 370-392. [Hungarian]
33. Gill, D. J., Freshman, A., Blender, J. A., et al.: The Montreal cognitive assessment as a screening tool for cognitive impairment in Parkinson's disease. Mov. Disord., 2008, 23(7), 1043-1046.
34. Kandiah, N., Zhang, A., Cenina, A. R., et al.: Montreal Cognitive Assessment for the screening and prediction of cognitive decline in early Parkinson's disease. Parkinsonism Relat. Disord., 2014, 20(11), 1145-1148.
35. Dalrymple-Alford, J. C., MacAskill, M. R., Nakas, C. T., et al.: The MoCA: well-suit ed screen for cognitive impairment in Parkinson disease. Neurology, 2010, 75(19), 1717-1725.
36. Van Steenoven, I., Aarsland, D., Hurtig, H., et al.: Conversion between Mini-Mental State Examinatio n, Montreal Cognitive Assessment, and Dementia Rating Scale-2 scores in Parkinson's disease. Mov. Disord., 2014, 29(14), 1809-1815.
37. Chou, K. L., Lenhart, A., Koeppe, R. A., et al.: Abnormal MoCA and normal range MMSE scores in Parkinson disease without dementia: cognitive and neurochemical correlates. Parkinsonism Relat. Disord., 2014, 20(10), 1076-1080.
38. Marras, C., Armstrong, M. J., Meaney, C. A., et al.: Measuring mild cognitive impairment in patients with Parkinson's disease. Mov. Disord., 2013, 28(5), 626-633.
39. McColgan, P., Evans, J. R., Breen, D. P., et al.: Addenbrooke's Cognitive Examination-Revised for mild cognitive impairment in Parkinson's disease. Mov. Disord., 2012, 27(9), 1173-1177.
40. Brown, G. G., Rahill, A. A., Gorell, J. M., et al.: Validity of the Dementia Rating Scale in assessing cognitive function in Parkinson's disease. J. Geriatr. Psychiatry Neurol., 1999, 12(4), 180-188.
41. Fehér, G., Balás, I., Komoly, S., et al.: Effectiveness of bilateral subthalamic stimulation in the mirror of c hanges in drug treatment of Parkinson's disease. [Akétoldali subthalamicus stimuláció hatékonysága az antiparkinson gyógyszerelés változtatásának tükrében.] Ideggyogy. Sz., 2010, 63(9-10), 314-319. [Hungarian]
42. Kovács, N., Aschermann, Zs., Nagy, F., et al.: Role of deep brain stimulation in the treatment of movement disorders. [Mély agyi stimuláció szerepe a mozgászavarok kezelésében.] Magy. Orv., 2011, 19(7-8), 32-34. [Hungarian]
43. Pirogovsky, E., Schiehser, D. M., Litvan, I., et al.: The utility of the Mattis Dementia Rating Scale in Parkinson's disease mild cognitive impairment. Parkinsonism Relat. Disord., 2014, 20(6), 627-631.
44. Matteau, E., Dupré, N., Langlois, M., et al.: Clinical validity of the Mattis Dementia Ra ting Scale-2 in Parkinson disease with MCI and dementia. J. Geriatr. Psychiatry Neurol., 2012, 25(2), 100-106.
45. Villeneuve, S., Rodrigues-Brazète, J., Joncas, S., et al.: Validity of the Mattis Dementia Rating Scale to detect mild cognitive impairment in Parkinson's disease and REM sleep behavior disorder. Dement. Geriatr. Cogn. Disord., 2011, 31(3), 210-217.
46. Schlosser Covell, G. E., Hoffman-Snyder, C. R., Wellik, K. E., et al.: Physica l activity level and future risk of mild cognitive impairment or dementia: a critically appraised topic. Neurologist, 2015, 19(3), 89-91.
47. Scarmeas, N., Luchsinger, J. A., Brickman, A. M., et al.: Physic al activity and Alzheimer disease course. Am. J. Geriatr. Psychiatry, 2011, 19(5), 471-481.
48. Grande, G., Vanacore, N., Maggiore, L., et al.: Physical activity reduces the risk of dementia in mild cognitive impairment subjects: a cohort study. J. Alzhei mers Dis., 2014, 39(4), 833-839.
49. Aarsland, D., Laake, K., Larsen, J. P., et al.: Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J. Neurol. Neurosurg. Psychiatry, 2002, 72(6), 708-712.
50. Kehagia, A. A., Barker, R. A., Robbins, T. W.: Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol., 2010, 9(12), 1200-1213.
51. Larsson, V., Engedal, K., Aarsland, D., et al.: Quality of life and the effect of memantine in dementia with lewy bodies and Parkinson's disease dementia. Dement. Geriatr. Cogn. Disord., 2011, 32(4), 227-234.
52. Rolinski, M., Fox, C., Maidment, I., et al.: Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst. Rev., 2012, 3, CD006504.
53. Devos, D., Moreau, C., Maltête, D., et al.: Rivastigmine in apathetic but dementia and depression- free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial. J. Neurol. Neurosurg. Psychiatry, 2014, 85(6), 668-674.
54. Kincses, P., Kovács, N., Karádi, K., et al.: Critic al issues of the biopsychosocial treatment of Parkinson's disease. [A Parkinsonkór biopszichoszociális ellátásának kritikus kérdései.] Orv. Hetil., 2015, 156(12), 472-478. [Hungarian]
55. Langenbahn, D. M., Ashman, T., Cantor, J., e t al.: An evidencebased review of cognitive rehabilitation in medical conditions affecting cognitive function. Arch. Phys. Med. Rehabil., 2013, 94(2), 271-286.
56. Cerasa, A., Quattrone, A.: The effectiveness of cognitive treatment in patients with Parkinson's d isease: a new phase for the neuropsychological rehabilitation. Parkinsonism Relat. Disord., 2015, 21(2), 165.
57. Reuter, I., Mehnert, S., Sammer, G., et al.: Efficacy of a multimodal cognitive rehabilitation including psychomotor and endurance train ing in Parkinson's disease. J. Aging Res., 2012, 2012, 235765.
58. Kalbe, E., Kessler, J.: Task force WANTED: Many reasons to promote research on cognitive rehabilitation to prevent, delay, and treat cognitive dysfunctions in patients with Parkinson's disease. Parkinsonism Relat. Disord., 2015, 21(2), 166-167.